Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "【Order On Telegram: @Chem2Door】Buy Methylone (M1, MDMC) Online In San Francisco,.7007"

Looking for quality documents?
external link icon
Repligen Reports Fourth Quarter and Year 2015 Financial Results
- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year -
- Gross margin expansion of 420 basis points to 57.8% for the year -
- Non-GAAP adjusted EPS of $0.40, an increase of 67% for the year - WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for the fourth quarter and year ended December 31, 2015. Below are the Company's performance highlights for these periods, followed by financial guidance for the year 2016 and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “2015 was a great year for Repligen, as we executed on our growth strategy and established the Repligen brand in key bioprocessing end-markets, while delivering strong financial performance across all of our product lines. For the year, we reported exceptional product sales
external link icon
Michael A. Griffith Appointed to Repligen Board of Directors
corporate icon
Charge Variant Analysis
Challenge: Charge heterogeneity in early development can affect efficacy and safety, but typical offline CEX or IEF methods are low throughput. Our Solution: ZipChip CE offers fast, high-resolution separation of charge variants to assess product consistency before scale-up.
external link icon
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 million Fourth quarter orders and revenues sequentially increased 11% and 8% respectively Orders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer of Repligen said, “During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13% excluding COVID, overcoming two points of currency headwind. Total orders outpaced sales by 6%,
external link icon
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658
external link icon
Repligen to Report Fourth Quarter and Full Year 2023 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2023 financial results on Wednesday, February 21, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve-month reporting periods ended December 31, 2023. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658
external link icon
Repligen Reports Fourth Quarter and Full Year 2022 Financial Results
Fourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currency
Full year revenue of $801.5 million represents year-over-year organic growth of 22% and 25% growth at constant currency Base business organic growth was 35% in the fourth quarter and 39% for the full year WALTHAM, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2022. Provided in this press release are financial highlights for the three- and twelve- month periods ended December 31, 2022, followed by our financial guidance for the year 2023, and access information for today’s webcast and conference call.
Tony J. Hunt, President and Chief Executive Officer of Repligen said, “I’m very pleased with our financial results and am especially encouraged by the performance of our base business
external link icon
Repligen to Report Fourth Quarter and Full Year 2022 Financial Results
Webcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2022 financial results on Wednesday, February 22, 2023. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2022. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the
external link icon
Repligen Reports Fourth Quarter and Full Year 2021 Financial Results
— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%
— Record revenue of $670.5 million for the year, and year-over-year growth of 83% — Organic revenue growth of 69% for the fourth quarter and 71% for the year 2021 — Completes acquisition of single-use fluid management component manufacturer BioFlex Solutions WALTHAM, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter and full year 2021. Provided in this press release are financial highlights for the three- and twelve-month periods ended December 31, 2021, followed by our financial guidance for the year 2022, and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are pleased with our financial results for both the fourth quarter and full year 2021, achieving year-over-year
external link icon
Repligen to Report Fourth Quarter and Full Year 2021 Financial Results
Webcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2021 financial results on Thursday, February 17, 2022. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2021.
The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the